Citi lowered its price target on the stock to $33 from $35 and maintained a ‘Neutral’ rating, according to The Fly. ・Hims reported a 40% jump in second-quarter revenue to $753 million, beating ...

Shares of Hims & Hers Health Inc HIMS edged lower in early trading on Tuesday, after the company reported mixed ...

Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target ...

The uncommitted facility provides Hims with a working-capital tool as it scales its healthcare and pharmacy operations.

Hims & Hers has been one of the most closely watched names in digital health this month. Between the FDA's peptide announcement, a Novo Nordisk settlement, and a flood of analyst revisions, the stock ...

The average one-year price target for Hims & Hers Health (NYSE:HIMS) has been revised to $30.00 / share. This is a decrease of 30.94% from the prior estimate of $43.45 dated February 1, 2026. The ...

Hims & Hers Health (HIMS) shares fell on the company's disappointing second-quarter earnings, overshadowing impressive ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Hims & Hers Health (NYSE:HIMS) absorbed another analyst ...

Shares of Hims & Hers Health fell more than 7% in premarket trading on Tuesday after the telehealth company reported a wider-than-expected second-quarter loss, as investments in branded GLP-1 ...

Hims & Hers Health Inc. HIMS is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four key peptides be added to a federal list that would allow compounding pharmacies to ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Shares of Hims & Hers Health (NYSE:HIMS) are under ...